Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation

Nucleic Acids Research

Volumn 43, Issue 16, 2015, Pages 7688-7701

  Yunn, Na Oh ^a   Koh, Ara ^a   Han, Seungmin ^a   Lim, Jong Hun ^a   Park, Sehoon ^a   Lee, Jiyoun ^a   Kim, Eui ^a   Jang, Sung Key ^a   Berggren, Per Olof ^a,b   Ryu, Sung Ho ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR KINASE; IR A48 APTAMER; OLIGONUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL;

ALLOSTERISM; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; CANCER CELL; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; GLUCOSE TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR BINDING; ADIPOCYTE; AGONISTS; ANIMAL; CELL LINE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADIPOCYTES; ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; APTAMERS, NUCLEOTIDE; BLOOD GLUCOSE; CELL LINE; CELL PROLIFERATION; GLUCOSE; HUMANS; MCF-7 CELLS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84942274883     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv767     Document Type: Article

References (57)

1. Tuerk, C. And Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
2. Ellington, A. D. And Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
3. Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D. And Trent, J. O. (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 86, 151-164.
4. Ng, E. W., Shima, D. T., Calias, P., Cunningham, E. T. Jr, Guyer, D. R. And Adamis, A. P. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 5, 123-132.
5. Sundaram, P., Kurniawan, H., Byrne, M. E. And Wower, J. (2013) Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci., 48, 259-271.
6. Luo, D. And Saltzman, W. M. (2000) Synthetic DNA delivery systems. Nat. Biotechnol., 18, 33-37.
7. Hopkins, A. L. And Groom, C. R. (2002) The druggable genome. Nat. Rev. Drug Discov., 1, 727-730.
8. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. And Vidal, M. (2007) Drug-target network. Nat. Biotechnol., 25, 1119-1126.
9. Youngren, J. F. (2007) Regulation of insulin receptor function. Cell. Mol. Life Sci., 64, 873-891.
10. Leto, D. And Saltiel, A. R. (2012) Regulation of glucose transport by insulin: Traffic control of GLUT4. Nat. Rev. Mol. Cell Biol., 13, 383-396.
11. American Diabetes Association. (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care, 33, S62-S69.
12. Lee, Y. J., Kim, I. S., Park, S. A., Kim, Y., Lee, J. E., Noh, D. Y., Kim, K. T., Ryu, S. H. And Suh, P. G. (2013) Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol. Ther., 21, 1004-1013.
13. Lollo, B., Steele, F. And Gold, L. (2014) Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics, 14, 638-644.
14. Lawrence, M. C., McKern, N. M. And Ward, C. W. (2007) Insulin receptor structure and its implications for the IGF-1 receptor. Curr. Opin. Struct. Biol., 17, 699-705.
15. Baer, K., Al-Hasani, H., Parvaresch, S., Corona, T., Rufer, A., Nolle, V., Bergschneider, E. And Klein, H. W. (2001) Dimerization-induced activation of soluble insulin/IGF-1 receptor kinases: An alternative mechanism of activation. Biochemistry, 40, 14268-14278.
16. Wilden, P. A., Kahn, C. R., Siddle, K. And White, M. F. (1992) Insulin receptor kinase domain autophosphorylation regulates receptor enzymatic function. J. Biol. Chem., 267, 16660-16668.
17. Gustafson, T. A., He, W., Craparo, A., Schaub, C. D. And O'Neill, T. J. (1995) Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol. Cell. Biol., 15, 2500-2508.
18. He, W., Craparo, A., Zhu, Y., O'Neill, T. J., Wang, L. M., Pierce, J. H. And Gustafson, T. A. (1996) Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J. Biol. Chem., 271, 11641-11645.
19. Tartare-Deckert, S., Murdaca, J., Sawka-Verhelle, D., Holt, K. H., Pessin, J. E. And Van Obberghen, E. (1996) Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF-I) receptor: Comparative study using the yeast two-hybrid system. Endocrinology, 137, 1019-1024.
20. Van Horn, D. J., Myers, M. G. Jr and Backer, J. M. (1994) Direct activation of the phosphatidylinositol 3-kinase by the insulin receptor. J. Biol. Chem., 269, 29-32.
21. Kerkhoff, E. And Rapp, U. R. (1998) Cell cycle targets of Ras/Raf signalling. Oncogene, 17, 1457-1462.
22. Pages, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S. And Pouyssegur, J. (1993) Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. U. S. A., 90, 8319-8323.
23. Lundby, A., Bolvig, P., Hegelund, A. C., Hansen, B. F., Worm, J., Lutzen, A., Billestrup, N., Bonnesen, C. And Oleksiewicz, M. B. (2015) Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues. J. Appl. Toxicol., 35, 842-850.
24. Shukla, A., Grisouard, J., Ehemann, V., Hermani, A., Enzmann, H. And Mayer, D. (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr. Relat. Cancer, 16, 429-441.
25. Taniguchi, C. M., Emanuelli, B. And Kahn, C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol., 7, 85-96.
26. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R. And Tsichlis, P. N. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81, 727-736.
27. Burgering, B. M. And Coffer, P. J. (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature, 376, 599-602.
28. Sanchez-Margalet, V., Goldfine, I. D., Vlahos, C. J. And Sung, C. K. (1994) Role of phosphatidylinositol-3-kinase in insulin receptor signaling: Studies with inhibitor, LY294002. Biochem. Biophys. Res. Commun., 204, 446-452.
29. Pratico, E. D., Sullenger, B. A. And Nair, S. K. (2013) Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther., 23, 35-43.
30. McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B. And Gilboa, E. (2008) Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest., 118, 376-386.
31. Dollins, C. M., Nair, S., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E. And Sullenger, B. A. (2008) Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol., 15, 675-682.
32. Huang, Y. Z., Hernandez, F. J., Gu, B., Stockdale, K. R., Nanapaneni, K., Scheetz, T. E., Behlke, M. A., Peek, A. S., Bair, T., Giangrande, P. H. et al. (2012) RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol. Pharmacol., 82, 623-635.
33. Kenakin, T. (2011) Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther., 336, 296-302.
34. Violin, J. D., Crombie, A. L., Soergel, D. G. And Lark, M. W. (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci., 35, 308-316.
35. Tennagels, N. And Werner, U. (2013) The metabolic and mitogenic properties of basal insulin analogues. Arch. Physiol. Biochem., 119, 1-14.
36. Ish-Shalom, D., Christoffersen, C. T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko, R. M., Naor, D. And De Meyts, P. (1997) Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia, 40(Suppl. 2), S25-S31.
37. Mannucci, E. (2012) Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol., 2012, 240634.
38. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. And Abbruzzese, J. L. (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-488.
39. Hemkens, L. G., Grouven, U., Bender, R., Gunster, C., Gutschmidt, S., Selke, G. W. And Sawicki, P. T. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia, 52, 1732-1744.
40. Bowker, S. L., Majumdar, S. R., Veugelers, P. And Johnson, J. A. (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-258.
41. Yang, Y. X., Hennessy, S. And Lewis, J. D. (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology, 127, 1044-1050.
42. Janghorbani, M., Dehghani, M. And Salehi-Marzijarani, M. (2012) Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm. Cancer, 3, 137-146.
43. Vigneri, R., Squatrito, S. And Frittitta, L. (2012) Selective insulin receptor modulators (SIRM): A new class of antidiabetes drugs? Diabetes, 61, 984-985.
44. Ottensmeyer, F. P., Beniac, D. R., Luo, R. Z. And Yip, C. C. (2000) Mechanism of transmembrane signaling: insulin binding and the insulin receptor. Biochemistry, 39, 12103-12112.
45. Hubbard, S. R., Mohammadi, M. And Schlessinger, J. (1998) Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem., 273, 11987-11990.
46. Hubbard, S. R., Wei, L., Ellis, L. And Hendrickson, W. A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature, 372, 746-754.
47. Bhaskar, V., Goldfine, I. D., Bedinger, D. H., Lau, A., Kuan, H. F., Gross, L. M., Handa, M., Maddux, B. A., Watson, S. R., Zhu, S. et al. (2012) A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes, 61, 1263-1271.
48. Jensen, M., Hansen, B., De Meyts, P., Schaffer, L. And Urso, B. (2007) Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J. Biol. Chem., 282, 35179-35186.
49. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. And Hemmings, B. A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J., 15, 6541-6551.
50. Hajduch, E., Alessi, D. R., Hemmings, B. A. And Hundal, H. S. (1998) Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes, 47, 1006-1013.
51. Cong, L. N., Chen, H., Li, Y., Zhou, L., McGibbon, M. A., Taylor, S. I. And Quon, M. J. (1997) Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol., 11, 1881-1890.
52. Kohn, A. D., Summers, S. A., Birnbaum, M. J. And Roth, R. A. (1996) Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem., 271, 31372-31378.
53. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. And Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
54. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. And Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell, 127, 125-137.
55. Gallay, N., Dos Santos, C., Cuzin, L., Bousquet, M., Simmonet Gouy, V., Chaussade, C., Attal, M., Payrastre, B., Demur, C. And Recher, C. (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia, 23, 1029-1038.
56. Vincent, E. E., Elder, D. J., Thomas, E. C., Phillips, L., Morgan, C., Pawade, J., Sohail, M., May, M. T., Hetzel, M. R. And Tavare, J. M. (2011) Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br. J. Cancer, 104, 1755-1761.
57. Kumar, A., Lawrence, J. C. Jr, Jung, D. Y., Ko, H. J., Keller, S. R., Kim, J. K., Magnuson, M. A. And Harris, T. E. (2010) Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes, 59, 1397-1406.